Expression of β2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: A longitudinal six month study

Journal of Neurology Neurosurgery and Psychiatry

Volumn 74, Issue 2, 2003, Pages 197-202

  Zoukos, Y ^a   Thomaides, T N ^b   Kidd, D ^c   Cuzner, M L ^d   Thompson, A ^e  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b Pamakaristos Hospital   (Greece)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CYANOIODOPINDOLOL; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ADULT; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; LIGAND BINDING; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR DENSITY; TH1 CELL; TIME SERIES ANALYSIS; BLOOD; BRAIN; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; MONOCYTE; PATHOLOGY; RADIOASSAY; SPINAL CORD;

ADULT; BRAIN; FEMALE; HUMANS; IODINE RADIOISOTOPES; IODOCYANOPINDOLOL; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC, BETA-2; SPINAL CORD; TH1 CELLS;

EID: 0037289749     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.74.2.197     Document Type: Article

References (41)

1. Elenkov IJ, Papanicolaou DA, Wilder RL, et al. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc Assoc Am Physicians 1996;108:374-81.
2. Panina-Bordignon P, Mazzeo D, Lucia PD, et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 1997;100:1513-19.
3. Hasko G, Szabo C, Nemeth ZH, et al. Stimulation of beta-adrenoceptors inhibits endotoxin-induced IL-12 production in normal and IL-10 deficient mice. J Neuroimmunol 1998;88:57-61.
4. Sandres VM, Baker RA, Ramer-Quinn DS, et al. Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. J Immunol 1997;158:4200-10.
5. Borger P, Hoekstra Y, Esselink MT, et al. Beta-adrenoceptor-mediated inhibition of IFN-gamma, IL-3 and GM-CSF mRNA accumulation in activated human T lymphocytes is solely mediated by beta2-adrenoceptor subtype. Am J Respir Cell Mol Biol 1998;19:400-7.
6. Hasko G, Elenkov U, Kvetan V, et al. Differential effect of selective block of alpha2-adrenoreceptors on plasma levels of tumour necrosis-alpha, inteleukin-6 and corticosterone induced by bacterial lipopolysaccharide in mice. J Endocrinol 1995;144:457-62.
7. Elenkov IJ, Hasko G, Kovacs KJ, el al. Modulation of lipopolysaccharide-induced tumour necrosis factor-alpha production by selective alpha and beta-adrenergic drugs in mice. J Neuroimmunol 1995;61:123-31.
8. Woiciechowsky C, Asadullah K, Nestller D, et al. Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med 1998;4:808-13.
9. Whalen MM, Bankhurst AD. Effects of beta-adrenergic receptor activation, cholera toxin and forskolin on human natural killer cell function. Biochem J 1990;272:327-31.
10. Hellestrand K, Hermodsson S. An immunopharmacological analysis of adrenaline-induced suppression of human natural killer cell cytotoxicity. Int Arch Allergy Appl Immunol 1989;89:334-41.
11. Karaszewski JW, Reder AT, Maselli R, et al. Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. Ann Neurol 1990;27:366-72.
12. - suppressor cell. Ann Neurol 1991;30:42-7.
13. Zoukos Y, Leonard JP, Thomaides T, et al. β-Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1. Ann Neurol 1992;31:657-62.
14. Zoukos Y, Kidd D, Woodroofe MN, et al. Increased expression of high affinity IL-2 receptors and β-adrenoceptors on peripheral blood mononuclear cells is associated with clinical and MRI activity in multiple sclerosis. Brain 1994;117:307-15.
15. Thompson AJ, Kermond AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
16. Kidd D, Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:15-19.
17. Duran I, Martinez-Caceres EM, Rio J, et al. Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules. Brain 1999;122:2297-307.
18. Prat A, Pelletier D, Duquette P, et al. Heterogeneity of T-lymphocyte function in primary progressive multiple sclerosis: relation to magnetic resonance imaging lesion volume. Ann Neurol 2000;47:234-7.
19. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
20. Matthews WB. Course and prognosis. In: Matthews WB, Martyn CN, Allen IV, et al, eds. McAlpine's multiple sclerosis. London: Churchill Livingstone, 1992:142-55.
21. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
22. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968:21(suppl):77.
23. Zoukos Y, Thomaides T, Mathias CJ, et al. High beta adrenoceptor density on peripheral blood mononuclear cells in progressive multiple sclerosis: a manifestation of autonomic dysfunction or inflammation? Acta Neurol Scand 1994:90:382-7.
24. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating disease. Annu Rev Immunol 1992;10:153-87.
25. Beck J, Rondot P, Catinot L, et al. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988;78:318-23.
26. Lu C-Z, Jensen MA, Arnason BGW. Interferon gamma- and interleukin-4-secreting cells in multiple sclerosis. J Neuroimmunol 1993;46:123-8.
27. Woodroofe MN, Cuzner ML. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 1993;5:583-8.
28. Windhagen A, Newcombe J, Dangond F, et al. Expression of costimulatory molecules B7-1 (CD80), B7-2(CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995;182:1985-96.
29. Rieckmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-8.
30. Byskosh PV, Reder AT. Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Multiple Sclerosis 1996;1:262-9.
31. Makhlouf K, Weiner HL, Khoury SJ. Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol [review]. CNS Drugs 2002;16:1-8.
32. Makhlouf K, Comabella M, Imitola J, et al. Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis. J Neuroimmunol 2001;117:156-65.
33. Thompson AJ, Kermode AG, MacManus DG, et al. Patterns of disease activity in multiple sclerosis: a clinical and magnetic resonance imaging study. BMJ 1990;300:631-4.
34. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain 1997;120:1085-96.
35. Stevenson VL, Miller DH, Leary SM, et al. One year follow up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68:713-8.
36. Lucchinetti CF, Bruck W, Rodriguez M, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996;6:259-74.
37. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:323-5.
38. Thorpe JW, Kidd D, Moseley IF, et al. Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain 1996;119:709-14.
39. Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993;43:2632-7.
40. Giovannoni G, Lai M, Thorpe J, et al. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology 1997:48:1557-65.
41. McDonnell GV, McMillan SA, Douglas JP, et al. Serum soluble adhesion molecules in multiple sclerosis: raised sVCAM-1, sICAM-1 and sE-selectin in primary progressive disease. J Neurol 1999;246:87-92.